1. Home
  2. ENTA vs HIO Comparison

ENTA vs HIO Comparison

Compare ENTA & HIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$13.93

Market Cap

374.6M

Sector

Health Care

ML Signal

HOLD

Logo Western Asset High Income Opportunity Fund Inc.

HIO

Western Asset High Income Opportunity Fund Inc.

HOLD

Current Price

$3.73

Market Cap

350.0M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTA
HIO
Founded
1995
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
374.6M
350.0M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
ENTA
HIO
Price
$13.93
$3.73
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$20.40
N/A
AVG Volume (30 Days)
110.8K
344.3K
Earning Date
05-11-2026
01-01-0001
Dividend Yield
N/A
10.33%
EPS Growth
29.93
N/A
EPS
N/A
N/A
Revenue
$102,814,000.00
N/A
Revenue This Year
$7.76
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
16.48
N/A
52 Week Low
$4.96
$3.52
52 Week High
$17.15
$4.05

Technical Indicators

Market Signals
Indicator
ENTA
HIO
Relative Strength Index (RSI) 54.19 57.25
Support Level $13.75 $3.65
Resistance Level $15.52 $3.89
Average True Range (ATR) 0.68 0.04
MACD 0.11 0.01
Stochastic Oscillator 63.77 89.47

Price Performance

Historical Comparison
ENTA
HIO

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About HIO Western Asset High Income Opportunity Fund Inc.

Western Asset High Income Oppor Fd Inc is a diversified closed-end management investment company. The company's primary objective is to seek high current income and the secondary objective is capital appreciation. It invests a majority of its net assets in high-yield corporate debt securities and the rest in common stock equivalents, including options, warrants, and rights. The company invests in securities of companies from various sectors such as energy, technology, utilities, industrials, communications, finance, and capital goods among others.

Share on Social Networks: